Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 27, Issue 11, 2008, Pages 1141-1143

  Nomura, K ^a,b   Fujimoto, Y ^a   Kanbayashi, Y ^a   Ikawa, K ^c   Taniwaki, M ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Kyoto Prefectural Institute of Public Health and Environment   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADULT; AGED; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; JAPAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MONTE CARLO METHOD; MYCOSES; PYRIMIDINES; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 55549101581     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-008-0543-1     Document Type: Article

References (10)

1. TJ Walsh P Pappas DJ Winston 2002 Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 225 234
2. D Andes K Marchillo T Stamstad 2003 In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model Antimicrob Agents Chemother 47 3165 3169
3. K Nomura N Morikawa K Ikawa 2008 Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis J Antimicrob Chemother 61 892 900 doi:10.1093/jac/dkn038
4. D Levêque Y Nivoix F Jehl 2006 Clinical pharmacokinetics of voriconazole Int J Antimicrob Agents 27 274 284
5. L Lindbom J Ribbing EN Jonsson 2004 Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming Comput Methods Programs Biomed 75 85 94
6. L Lindbom P Pihlgren EN Jonsson 2005 PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM Comput Methods Programs Biomed 79 241 257
7. MA Pfaller RN Jones GV Doern 1999 International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe) Diagn Microbiol Infect Dis 35 19 25
8. MA Pfaller SA Messer RJ Hollis 2002 In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46 1723 1727
9. U Theuretzbacher F Ihle H Derendorf 2006 Pharmacokinetic/pharmacodynamic profile of voriconazole Clin Pharmacokinet 45 649 663
10. Y Ikeda K Umemura K Kondo 2004 Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status Clin Pharmacol Ther 75 587 588